Clearing amyloid through the blood-brain barrier

Journal of Neurochemistry

Volumn 89, Issue 4, 2004, Pages 807-811

  Zlokovic, Berislav V ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Alzheimer's amyloid peptide; Blood brain barrier; Clearance; Lipoprotein receptor; RAGE

Indexed keywords

ALPHA 2 MACROGLOBULIN; AMYLOID; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; BETA SECRETASE; BLOOD CLOTTING FACTOR 8; BRAIN PROTEIN; CHOLESTEROL; ENDOTHELIN CONVERTING ENZYME; GAMMA SECRETASE; GELATINASE B; GELSOLIN; IMMUNOGLOBULIN RECEPTOR; INSULINASE; LACTOFERRIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MEMBRANE METALLOENDOPEPTIDASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY M266; OLIGOMER; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN ANTIBODY; PROTEINASE; RAGE PROTEIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR;

ALZHEIMER DISEASE; ANALYTIC METHOD; BIOACCUMULATION; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; EXPERIMENTAL MODEL; HUMAN; MEMBRANE TRANSPORT; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEIN TRANSPORT; SHORT SURVEY; TRANSPORT KINETICS; ANIMAL; BRAIN; METABOLISM; REVIEW; VASCULARIZATION;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PROTEIN; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; HUMANS; LDL-RECEPTOR RELATED PROTEINS; RECEPTORS, IMMUNOLOGIC;

EID: 2542475986     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2004.02385.x     Document Type: Short Survey

References (32)

1. 40 in the squirrel monkey: a SPECT study in a primate model of cerebral amyloid angiopathy. J. Drug Targeting 10, 359-368.
2. Begley D. and Brightman M. (2003) Structural and functional aspects of the blood-brain barrier, In: Progress in Drug Research, Vol. 61 (L. Prokai and K. Prokai-Tatrai, eds). Birkhause Velag, Basel.
3. Carro E., Trejo J., Gomez-Isla T., LeRoith D. and Torres-Aleman I. (2002) Serum insulin-like growth factor I regulates brain amyloid-β levels. Nature Med. 8, 1390-1397.
4. Deane R., Yan S., Submamaryan R., LaRue B., Jovanovic S., Hogg E., Welch D., Manness L., Lin C., Yu J. et al. (2003) RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 9, 907-913.
5. DeMattos R., Bales K., Cummins D., Paul S. and Holtzman D. (2002a) Brain to plasma amyloid-β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295, 2264-2267.
6. DeMattos R., Bales K., Parsadanian M., O'Dell M., Foss E., Paul S. and Holtzman D. (2002b) Plaque-associated disruption of CSF and plasma amyloid-β equilibrium in a mouse model of Alzheimer's disease. J. Neurochem. 81, 229-236.
7. DeMattos R., Bales K., Paul S. and Holtzman D. (2003) Potential role of endogenous and exogenous Aβ binding molecules in Aβ clearance and metabolism, In: Aβ Metabolism in Alzheimer's Disease (Saido T. ed). Landes Bioscience, Georgetown, TX, USA.
8. Ghiso J. and Frangione B. (2002) Amyloidosis in Alzheimer's Disease. Adv. Drug Del Rev. 54, 1539-1553.
9. Hardy J. and Selkoe D. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356.
10. Herz J. (2003) Coaxing the LDL receptor family into the fold. Cell 112, 289-292.
11. Iwata N., Tsubuki S., Takaki Y., Shirotani K., Lu B., Gerard N., Gerard C., Hama E., Lee H.-J. and Saido T. C. (2001) Metabolic regulation of brain Aβ by neprilysin. Science 292, 1550-1552.
12. Kang D., Saitoh T., Chen X., Xia Y., Masliah E., Hansen L., Thomas R., Thal L. J. and Katzman R. (1997) Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset alzheimer's disease. Neurology 49, 56-61.
13. Kawarabayashi T., Younkin L., Saido T., Shoji M., Ashe K. and Younkin S. (2001) Age-dependent changes in brain, CSF, and plasma amyloid β protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 21, 372-381.
14. Kuo Y., Emmerling M., Lampert H., Hempelman S., Kokjohn T., Woods A., Cotter R. and Roher A. (1999) High levels of circulting Aβ42 are sequestered by plasma proteins in Alzheimer's disease. Biochem. Biophys. Res. Comm. 257, 787-791.
15. Lam F. C., Liu R., Lu P. H., Shapiro A. B., Renoir J. M., Sharom F. J. and Reiner P. B. (2001) β-Amyloid efflux mediated by p-glycoprotein. J. Neurochem. 76, 1121-1128.
16. Mackic J., Ghiso J., Frangione B., Kirkman L., Bading J. and Zlokovic B. (2002) Differential cerebrovascular sequestration and enhanced blood-brain barrier permeability to circulating Alzheimer's amyloid-β peptide in aged Rhesus vs. aged Squirrel monkey. Vascular Pharmacol. 18, 303-313.
17. Matsubara E., Ghiso J., Frangione B., Amari M., Tomidokoro Y., Ikeda Y., Harigaya Y., Okamoto K. and Shoji M. (1999) Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome. Ann. Neurol. 45, 537-541.
18. Matsuoka Y., Saito M., LaFrancois J. et al. (2003) Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to β-amyloid. J. Neurosci. 23, 29-33.
19. Monro O., Mackic J., Yamada S., Segal M., Ghiso J., Maurer C., Calero M., Frangione B. and Zlokovic B. (2002) Substitution at codon 22 reduces clearance of Alzheimer's amyloid-β peptide from the cerebrospinal fluid and prevents its transport from the central nervous system into blood. Neurobiol. Aging 23, 405-412.
20. Pepys M., Herbert J., Hutchinson G. et al. (2002) Targeted pharmacological deletion of serum amyloid P component for treatment of human amyloidosis. Nature 417, 254-259.
21. Pietrzik C., Busse T., Merriam D., Weggen S. and Koo E. (2002) The cytoplasmic domain of the LDL receptor-related protein regulates multiple steps in APP processing. EMBO J. 21, 5691-5700.
22. Selkoe D. (1998) The cell biology of beta-amyloid precursor protein and presenlin in Alzheimer's disease. Trends Cell Biol. 8, 447-453.
23. Selkoe D. (2001) Clearing the brain's amyloid cobwebs. Neuron 32, 177-180.
24. 1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 106, 1489-1499.
25. Sigurdsson E., Scholtzova H., Mehta P., Frangione B. and Wisniewski T. (2001) Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am. J. Pathol. 159, 439-447.
26. Silverberg G., Mayo M., Saul T., Rubenstein E. and McGuire D. (2003) Alzheimer's disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis. Lancet Neurol. 2, 506-511.
27. Van Uden E., Mallory M., Veinbergs I., Alford M., Rockenstein E. and Masliah E. (2002) Increased extracellular amyloid deposition and neurodegeneration in human amyloid precursor protein transgenic mice deficient in receptor-associated protein. J. Neurosci. 22, 9298-9304.
28. Vassar R., Bennett B., Babu-Khan S. et al. (1999) Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735-741.
29. Vogelgesang S., Cascorbi I., Schroeder E., Pahnke J., Kroemer H. K., Siegmund W., Kunert-Keil C., Walker L. and Warzok R. W. (2002) Deposition of Alzheimer's β-amyloid is inversely correlated with p-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 12, 535-541.
30. Walsh D., Klyubin I., Fadeeva J., Cullen W., Anwyl R., Wolfe M., Rowaan M. and Selkoe D. (2002) Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539.
31. Yan S., Zhu H., Zhu A., Du Golabek A. H., Roher A., Yu J., Soto C., Schmidt A., Stern D. and Kindy M. (2000) Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat. Med. 6, 643-651.
32. Zlokovic B., Martel C., Matsubara E., McComb J., Zheng G., McCluskey R., Frangione B. and Ghiso J. (1996) Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer's disease amyloid-β at the blood-brain and blood-cerebrospinal fluid barriers. Proc. Natl Acad. Sci. USA 93, 4229-4234.